Rapid amyloid-β clearance and cognitive recovery by modulating BBB transport
a day ago
- #Alzheimer's disease
- #Blood-brain barrier
- #Nanomedicine
- The blood-brain barrier (BBB) plays a crucial role in protecting the central nervous system (CNS) and is implicated in Alzheimer’s disease (AD) pathogenesis due to dysfunction leading to amyloid-β (Aβ) accumulation.
- A novel therapeutic strategy targets low-density lipoprotein receptor-related protein 1 (LRP1) on the BBB using multivalent LRP1-targeted polymersomes (A40-POs) to enhance Aβ clearance via transcytosis.
- In AD model mice, A40-POs reduced brain Aβ levels by nearly 45% and increased plasma Aβ levels by 8-fold within 2 hours, demonstrating rapid and effective clearance.
- Cognitive assessments showed significant improvements in spatial learning and memory in treated AD mice, with effects lasting up to 6 months post-treatment.
- The study highlights the potential of BBB modulation and LRP1-mediated Aβ clearance as a transformative approach for AD therapy, emphasizing the importance of repairing BBB function rather than merely bypassing it.